The IAS–USA Annual Update on HIV Management in Atlanta, Georgia (Offered In Person and Virtually)

Last Modified: Nov 10, 2026 @ 2:51 PM

Program Description

Stay current with the latest advances in HIV care at the IAS–USA Annual Update on HIV Management in Atlanta. This 1-day hybrid course for clinicians caring for people with HIV brings together leading experts for timely clinical updates, practical guidance, and engaging case-based discussions. The program will highlight key findings from CROI 2027 and other recent developments, including new and investigational antiretroviral drugs, with an emphasis on long-acting formulations. Faculty will also review advances in HIV and sexually transmitted infection (STI) prevention—including preexposure prophylaxis (PrEP), postexposure prophylaxis (PEP), and doxycycline postexposure prophylaxis (doxyPEP)—and explore challenging antiretroviral therapy (ART) cases.

Additional sessions will address cardiovascular disease prevention beyond REPRIEVE, human papillomavirus (HPV)–related disease and anal cancer prevention, and emerging pharmacologic treatments for substance use disorders.

Join us in person in Atlanta or virtually for a focused day of expert insights, interactive discussion, and practical strategies for clinical practice.

Assessment of Needs

Rapid advances in HIV management require clinicians to stay current with evolving evidence and recommendations. This course will examine how new findings inform the management of HIV and related comorbidities. Expert HIV clinicians and researchers will present the content through didactic lectures, clinically relevant cases, and panel discussions.

Learning Objectives

After participating in the activity, learners will be able to:

• Implement recommendations for initiating or modifying ART in challenging clinical circumstances, including drug resistance patterns and other factors that influence treatment selection
• Apply current recommendations for HIV and STI prevention—including PrEP, PEP, and doxyPEP—in clinical practice
• Integrate key findings from CROI 2027 into HIV care
• Utilize current guidance on HPV vaccination, anal cancer screening, and the management of HPV-related disease
• Evaluate emerging pharmacologic treatments for alcohol, stimulant, and opioid use disorders

Preliminary Topics

• Challenging cases in antiretroviral therapy
• Key updates from CROI 2027
• Advances in HIV prevention
• New and investigational antiretroviral drugs, with an emphasis on long-acting formulations
• HPV-related disease: anal cancer and HPV vaccination
• Cardiovascular disease prevention beyond REPRIEVE
• Pharmacologic treatment of substance use disorders

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity to receive a refund minus a $15 administrative fee. Any requests made within 13 days before the course will not be refunded. Please note: registration substitutions are not permitted.